Larazotide Acetate (CAS 881851-50-9) – Wholesale & Research Grade
Larazotide acetate, also known as AT-1001, is a novel peptide-based drug primarily investigated for its potential therapeutic applications in treating celiac disease. This compound acts as a tight junction modulator, which helps restore the integrity of the intestinal barrier, a crucial factor in managing the symptoms associated with gluten sensitivity.
Research Applications
Research on larazotide acetate has focused on its ability to mitigate the immune response triggered by gluten exposure in individuals with celiac disease. Clinical trials have demonstrated that this compound can significantly reduce gastrointestinal symptoms and improve the quality of life for patients. Furthermore, larazotide acetate is being explored for its potential use in other gastrointestinal disorders, particularly those characterized by increased intestinal permeability.
Mechanism of Action
The mechanism of action for larazotide acetate involves its role as a tight junction enhancer. By modulating the epithelial barrier function, it prevents the translocation of gluten peptides across the intestinal epithelium, thereby reducing the inflammatory response. This mechanism is particularly beneficial for individuals with celiac disease, where gluten ingestion leads to an autoimmune response resulting in intestinal damage.
Solubility and Storage Advice
Larazotide acetate is soluble in water, making it suitable for formulation in various delivery systems. For optimal stability, it should be stored in a cool, dry place, away from direct sunlight. It is advisable to keep the compound in tightly sealed containers to prevent degradation and maintain its efficacy for future applications.
Future Research Directions
Future research on larazotide acetate is likely to focus on expanding its therapeutic indications beyond celiac disease, potentially exploring its use in other inflammatory bowel diseases and conditions characterized by altered gut permeability. Additionally, ongoing studies may investigate the long-term safety and efficacy of larazotide acetate in diverse patient populations, as well as its potential combination with other therapies to enhance treatment outcomes.
| CAS Number | 881851-50-9 |
|---|---|
| Formula | C34H59N9O12 |
| Mol. Weight | 785.9 g/mol |
| IUPAC Name | acetic acid;2-[[(2S)-1-[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[(2-ami... |
| Grade | HPLC ≥98% |
Synthesis & Storage
Larazotide Acetate is supplied as a lyophilized powder to ensure stability during transit.
For long-term storage of CAS 881851-50-9, we recommend maintaining at -20°C.
Researchers must reconstitute this peptide with bacteriostatic water or sterile solvent only when ready for use.
Quality Control: All batches undergo rigorous HPLC purity testing (≥98%) prior to dispatch from our USA fulfillment center.